Oncology

Latest News

Within 5 years, the risk of SCC in particular was heightened among patients with MMP. | Image credit: wavebreak3 - stock.adobe.com

Rare Autoimmune Disorder Linked With Increased Risk of Certain Skin Cancers

By AJMC Contributor

April 21st 2025

The risk of some skin cancers, including squamous cell carcinoma, basal cell carcinoma, and non-melanoma skin cancer, was particularly heightened among patients with severe mucous membrane pemphigoid.

AI technology | Image: Adobe Stock

Tech Updates: McKesson Launches Precision Oncology Consortium; Financing for RISA Labs PA Platform

By Mary Caffrey

April 17th 2025

IVBM Atlanta | Image credit: AJMC

Making Novel Cancer Therapies Available Requires Choices Because Resources Are Limited

April 14th 2025

Businessman shows medical network wooden block for health, medicine, insurance, healthcare, care, concept. Medical technology services to solve public - ภัทรชัย รัตนชัยวงค์ - stock.adobe.com.jpeg

NCCN Data Find Racial, Socioeconomic Disparities in Quality of Care for Metastatic Pancreatic Cancer

By Giuliana Grossi

April 9th 2025

AJMC

Comparing Breast Cancer Treatment Outcomes Between Fee-for-Service and Medicare Advantage

By Galen Shearn-Nance, BS
Rishi R. Sachdev, BS

April 4th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

August 30th 2016

Translating a Radiologist's Visual Expertise Into Improving CAD

Surabhi Dangi-Garimella, PhD

Scientists at Brigham and Women’s Hospital are evaluating the depth of a trained radiologist’s eye to detect abnormalities on a mammogram, in an attempt to improve screening and earlier detection of disease.

August 30th 2016

Cancer Risk Increases the Longer a Woman Is Overweight or Obese

A study found that the longer a woman is overweight or obese, the higher the risk of developing several forms of cancer, plus the degree of being overweight plays a role in the risk of developing cancer.

August 29th 2016

PIONEER Trial: Hope for Patients With Unresectable Pancreatic Cancer

Surabhi Dangi-Garimella, PhD

Researchers at Cancer Research UK have developed a strategy to make pancreatic cancer more responsive to chemotherapy and radiation.

August 29th 2016

Infographic: How Young Adult Cancer Survivors Are Hit Hard by Treatment Costs

Laura Joszt, MA

In the August issue of Evidence-Based Oncology, The Samfund's Samantha Watson, MBA, and Michelle Landwehr, MPH, outline how young adult cancer survivors are disproportionately affected by treatment costs. This infographic breaks down the vicious cycle these patients get stuck in.

August 29th 2016

A Thaw in the US—Cuba Relation Could Yield a Lung Cancer Vaccine

Surabhi Dangi-Garimella, PhD

A vaccine, under development in Cuba for more than 2 decades, has shown potential to improve survival in patients with advanced non-small cell lung cancer.

August 26th 2016

Report in NEJM Links 8 More Cancers With Obesity

Researchers found a dose-response relationship for several cancers involved in eating, meaning the higher the weight, the greater risk of cancer.

August 26th 2016

5 Ongoing Initiatives at the FDA

Surabhi Dangi-Garimella, PhD

The FDA has several projects under its wings that can improve the regulatory aspect of drug development and healthcare overall.

August 25th 2016

Does Precision Medicine Aid or Complicate Treatment Decisions in Cancer?

Surabhi Dangi-Garimella, PhD

Based on the results of the MINDACT trial, investigators have concluded that chemotherapy is unnecessary in women with early-stage breast cancer who have a high clinical and low genomic risk of disease recurrence.

August 25th 2016

Dynamic Nature of Breast Cancer Resistance: The HER2 Switch

Surabhi Dangi-Garimella, PhD

Research at Massachusetts General Hospital has provided vital leads that can explain drug resistance observed in breast cancer.

August 24th 2016

Overdiagnosis Blamed for Global Increase in Thyroid Cancer

Surabhi Dangi-Garimella, PhD

Researchers from Italy and France have coauthored an article in the New England Journal of Medicine that blames novel diagnostic technologies, increased access to healthcare services, and increased medical surveillance for the thyroid cancer epidemic around the world

August 23rd 2016

The Final Word Is Out: Menopausal HRT Triples the Risk of Breast Cancer

Surabhi Dangi-Garimella, PhD

A new study by researchers at the Institute of Cancer Research has substantiated that hormone replacement using estrogen and progesterone increases the risk of breast cancer, especially with longer use.

August 22nd 2016

Researchers Propose a Bundled Payment Model for Breast Screening

Surabhi Dangi-Garimella, PhD

A new report by the Harvey L. Neiman Health Policy Institute recommends a bundled payment model for breast cancer screening, with the objective of improved patient care and a more efficient use of healthcare resources.

August 22nd 2016

Adverse Sociodemographic Conditions Reduce Survival in Younger Patients With Multiple Myeloma

Surabhi Dangi-Garimella, PhD

Factors such as insurance status and being married are significant determinants of survival compared with race/ethnicity, in patients with multiple myeloma who are less than 65 years of age.

This Week in Managed Care: August 20, 2016

August 20th 2016

This Week in Managed Care: August 20, 2016

This week, the top stories in managed care included Aetna's announcement that it was pulling back its participation on the Affordable Care Act exchanges, the annual meeting of the American Association of Diabetes Educators outlined how existing sites can help roll out the Diabetes Prevention Program nationwide, and hospital leaders gave their opinions on CMS' hospital readmission program.

August 19th 2016

The Toll of Cancer Care - Clinical and Financial Toxicity

Joseph Alvarnas, MD

This issue of Evidence-Based Oncology is dedicated to understanding the implications, scope, and opportunities within the realm of cost sharing in oncology.

August 19th 2016

Does the Cost-Sharing Burden Influence Cancer Outcomes?

Surabhi Dangi-Garimella, PhD

Financial burden is a potential nonclinical adverse event in cancer patients. As patients, especially those in the lower income ranges and the middle class, struggle to meet their medical bills, the likelihood of them skipping doses or doctor’s visits is quite high.

August 19th 2016

Young Adult Cancer Survivors Disproportionately Affected by Treatment Costs

Samantha Watson, MBA Michelle Landwehr, MPH

Young adult (YA) cancer survivors are hit the hardest in the wallet by their treatment. The average net worth of YAs who have received grants from The Samfund is a staggering —$35,000, while their counterparts in the general population is $68,000

August 19th 2016

Precision Oncology: Why Payers Should Initiate CGP Coverage Now!

Jerry Conway Ingrid Marino, MS, CGC

Precision oncology, or the clinically and financially efficient use of genomically matched treatments and clinical trials, is evolving as a potentially important starting point for cancer care within successful alternative payment models.

August 19th 2016

Proton Therapy Eliminates Unnecessary Radiation Exposure and Is Medically Necessary

Steven J. Frank, MD

When it comes to health coverage, most Americans face an unnerving reality-they have no idea what is covered under their health insurance policy until after they are affected by illness or disease.

August 19th 2016

Patient Access to Reference Pricing Prompts Choice of Lower-Cost Testing Laboratories, Cost Savings

Surabhi Dangi-Garimella, PhD

A study by researchers at the University of California, Berkeley, found that patients who have access to the prices charged by a testing laboratory, as well as reference pricing, choose lower-cost laboratories, a move that results in overall cost savings.

August 19th 2016

California Experiment Will Let Pathologists Report Cancer Diagnoses in Real Time

Surabhi Dangi-Garimella, PhD

A collaborative pilot that involves the California Department of Public Health, St. Joseph Health in Orange County, and UCSF Benioff Children’s Hospital in Oakland is studying whether near—real-time reporting of cancer diagnoses by pathologists, using standardized electronic forms, will permit providers to make more informed and timely treatment decisions.

August 19th 2016

Breakthrough for Daratumumab for Use as Second-Line Treatment With Standard of Care in Multiple Myeloma

Surabhi Dangi-Garimella, PhD

The monoclonal antibody daratumumab (Darzalex) has been granted Breakthrough designation, the second for this drug, for use in combination with either lenalidomide (Revlimid) and dexamethasone or bortezomib (Velcade) and dexamethasone for patients with multiple myeloma who have received at least 1 prior therapy.

August 19th 2016

The Risk of T2D in Individuals With Benign Adrenal Tumors

Surabhi Dangi-Garimella, PhD

Adrenal gland tumors that are defined as being nonfunctional may not really be so, and the hormones that these tumors secrete could increase an individual’s risk of cardiometabolic irregularities, according to a new study.

August 19th 2016

Nivolumab Passes QOL Test in Melanoma

Surabhi Dangi-Garimella, PhD

Results from the CheckMate 066 study found that the checkpoint inhibitor nivolumab, which has proven highly efficient in the treatment of melanoma, also performs well in improving the patient’s long-term quality of survival benefit in patients with advanced melanoma.

August 19th 2016

NEJM Study First to Identify Mutations Responsible for Relapse in PD-1 Inhibitor—Treated Melanoma

Surabhi Dangi-Garimella, PhD

Loss-of-function mutations in Janus kinase 1 (JAK1) or Janus kinase 2 (JAK2), deletion of the wild-type allele of JAK1 or JAK2, and truncation in the antigen-presenting protein beta-2-microglobulin (B2M) gene have been found responsible for lack of response to interferon gamma in patients with melanoma.

August 19th 2016

Paying to Make Health IT Meaningful: A Discussion at the NCCN Policy Summit

Surabhi Dangi-Garimella, PhD

Maximizing the utility of technology platforms and making them meaningful to ensure quality cancer care was the underlying theme of Emerging Issues and Opportunities in Health Information Technology, a National Comprehensive Cancer Network Policy Summit, held June 27, 2016, in Washington, DC.

August 19th 2016

Health IT Essential for the Success of Cancer Moonshot

Surabhi Dangi-Garimella, PhD

Gregory C. Simon, executive director, White House Cancer Task Force, spoke at the National Comprehensive Cancer Network Policy Summit in Washington, DC. “Just like the original moonshot, the Cancer Moonshot is about using technology and the resulting information,” he said.

August 19th 2016

Dissolving Data Silos and Improving Access to Health IT Essential in Oncology Care

Surabhi Dangi-Garimella, PhD

At the Emerging Issues and Opportunities in Health Information Technology Policy Summit hosted by the National Comprehensive Cancer Network, on June 27, 2016, an afternoon panel discussed the role of technology and its importance in promoting dissemination of data.

August 19th 2016

Patients With Early Stage Lung Cancer More Susceptible to Dying Due to Air Pollution

Surabhi Dangi-Garimella, PhD

Survival in patients with early-stage lung cancer, particularly those with adenocarcinomas, may be shortened by air pollution, according to a study published in the journal Thorax.

Dr Michael Kolodziej on New Immuno-Oncology Agents And Payment Plans

August 18th 2016

Dr Michael Kolodziej on New Immuno-Oncology Agents And Payment Plans

The key in making coverage decisions about the integration of immuno-oncology agents into payment plans is being able to identify the patients who are most likely to benefit while also considering the long-term need for the acceptance of innovation in cancer care when faced with economic constraints, said Michael Kolodziej, MD, national medical director for oncology strategy at Aetna.

...

91 92 93 94 95 96 97 98 99

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions